Investment bank RBC Capital Markets has issued a fresh take on Lonza, the Swiss contract drug manufacturer, arguing that the company's stock is being priced like an average contract development and manufacturing organization (CDMO) even though the market for its core services looks set to stay tight for years. The analysis highlights a disconnect between Lonza's growth prospects and its current valuation.
What Is a CDMO and Why Does Capacity Matter?
Lonza is a CDMO, meaning it makes biologic drugs and other complex medicines for pharmaceutical companies that prefer to outsource production rather than build their own factories. This model allows drugmakers to scale up quickly without massive capital expenditure. The key metric for investors in this space is capacity utilization: when factories are full, CDMOs can charge higher prices and grow profits. When capacity is loose, pricing power weakens.
RBC's latest capacity model suggests that supply and demand for biologics manufacturing are “matched tightly” from 2026 through 2029. After that, demand is likely to pull ahead unless the industry invests roughly $30 billion in new capacity over the next two to three years. That kind of spending would be a major undertaking, and it underscores the structural demand for Lonza's services.
Antibody-drug conjugates (ADCs)—a class of cancer therapies that combine a targeting antibody with a potent drug payload—are a particularly fast-growing segment. Lonza has significant exposure to ADC manufacturing, which adds another layer of growth potential.
Why Lonza's Stock Looks Cheap
Despite these tailwinds, Lonza's shares trade at a discount relative to other CDMOs. RBC attributes this to the market treating Lonza as a generic contract manufacturer rather than a specialized player with high barriers to entry. The bank notes that Lonza's earnings continue to climb, which should eventually force a re-rating if capacity remains tight.
For everyday investors, the implication is that Lonza may offer a more attractive risk-reward profile than its current valuation suggests. However, the CDMO sector is not without risks. A sudden slowdown in drug development, regulatory setbacks, or a wave of new factory construction by competitors could erode pricing power. The broader market backdrop also matters: rising interest rates can make the capital-intensive CDMO business more expensive to operate, and any economic downturn could pressure pharma budgets.
In a market where many growth stocks have been punished by higher rates, Lonza's discount may partly reflect that macro caution. But RBC's analysis argues that the fundamental demand story is strong enough to overcome those headwinds.
What It Means for Investors
For those holding Lonza shares, the RBC note provides a bullish counterpoint to the stock's recent underperformance. The key takeaway is that the company's earnings trajectory and the industry's capacity constraints could support higher valuations over time. Investors should watch for Lonza's next earnings report for signs of continued revenue growth and margin expansion.
It's also worth noting that the broader CDMO industry has seen consolidation and investment from large pharma companies looking to secure supply chains. Lonza's position as a leading player could make it a beneficiary of that trend. However, the $30 billion investment figure cited by RBC highlights the scale of the challenge: if the industry fails to add enough capacity, Lonza could face bottlenecks that limit growth. Conversely, if too much capacity comes online, pricing could suffer.
For now, the tight capacity outlook through 2029 gives Lonza a long runway. Investors should weigh that against the risks of execution, competition, and macro conditions. As always, diversification remains key: no single stock should dominate a portfolio, even one with a compelling growth story.
